Compare
4D Molecular Therapeutics, Inc. vs MeiraGTx Holdings plc vs Autolus Therapeutics plc vs Recursion Pharmaceuticals, Inc.
| Latest fiscal year | 4D Molecular Therapeutics, Inc. FDMT | MeiraGTx Holdings plc MGTX | Autolus Therapeutics plc AUTL | Recursion Pharmaceuticals, Inc. RXRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $85.21M | $81.39M | $75.39M | $74.68M |
| Revenue growth (YoY) | n/m | +144.6% | +644.9% | +26.9% |
| Gross margin | n/a | n/a | -27.8% (computed) | 5.0% (computed) |
| Operating margin | -187.2% | -130.2% | -358.9% | -867.9% |
| Net margin | -164.4% | -140.3% | -381.4% | -863.4% |
| Net income | -$140.11M | -$114.20M | -$287.53M | -$644.76M |
| EPS (Diluted) | -$2.42 | -$1.42 | -$1.08 | -$1.44 |
| Operating cash flow | -$109.08M | -$46.36M | -$283.57M | -$371.81M |
| Free cash flow | -$109.62M | -$50.19M | -$302.61M | -$378.28M |
| Cash & equivalents | $60.24M | $65.93M | $104.13M | $743.29M |
| Total assets | $566.71M | $244.43M | $589.07M | $1.47B |
| Total liabilities | $61.05M | $250.22M | $410.94M | $343.26M |
| Shareholders' equity | $505.66M | -$5.79M | $178.13M | $1.13B |
| Return on year-end equity | -27.7% | n/a | -161.4% | -57.0% |
| Shares outstanding | 57.61M | 81.12M | n/a | 528.18M |
Revenue, most recent five fiscal years
| Fiscal year | 4D Molecular Therapeutics, Inc. | MeiraGTx Holdings plc | Autolus Therapeutics plc | Recursion Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $85.21M Ended 2025-12-31 | $81.39M Ended 2025-12-31 | $75.39M Ended 2025-12-31 | $74.68M Ended 2025-12-31 |
| 1 year earlier | $37.0K Ended 2024-12-31 | $33.28M Ended 2024-12-31 | $10.12M Ended 2024-12-31 | $58.84M Ended 2024-12-31 |
| 2 years earlier | $20.72M Ended 2023-12-31 | $14.02M Ended 2023-12-31 | $1.70M Ended 2023-12-31 | $44.58M Ended 2023-12-31 |
| 3 years earlier | $3.13M Ended 2022-12-31 | n/a | n/a | $39.84M Ended 2022-12-31 |
| 4 years earlier | $18.04M Ended 2021-12-31 | n/a | n/a | $10.18M Ended 2021-12-31 |